These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 11295927)

  • 21. Circulating endothelin-3 levels in patients with sickle cell disease during hydroxyurea treatment.
    Makis AC; Hatzimichael EC; Kolios G; Bourantas KL
    Haematologica; 2004 Mar; 89(3):360-1. PubMed ID: 15020278
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hydroxyurea in very young children with sickle cell anemia is not a cure-all.
    Powars DR
    J Pediatr; 2001 Dec; 139(6):763-4. PubMed ID: 11743496
    [No Abstract]   [Full Text] [Related]  

  • 23. Hydroxyurea-induced leg ulcers: is macroerythrocytosis a pathogenic factor?
    Vélez A; García-Aranda JM; Moreno JC
    J Eur Acad Dermatol Venereol; 1999 May; 12(3):243-4. PubMed ID: 10461646
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Examining the effectiveness of hydroxyurea in people with sickle cell disease.
    Lanzkron S; Haywood C; Fagan PJ; Rand CS
    J Health Care Poor Underserved; 2010 Feb; 21(1):277-86. PubMed ID: 20173269
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pulmonary hypertension in children and young adults with sickle cell disease: evidence for familial clustering.
    Dahoui HA; Hayek MN; Nietert PJ; Arabi MT; Muwakkit SA; Saab RH; Bissar AN; Jumaa NM; Farhat FS; Dabbous IA; Bitar FF; Abboud MR
    Pediatr Blood Cancer; 2010 Mar; 54(3):398-402. PubMed ID: 19827138
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modulation of erythrocyte arginase activity in sickle cell disease patients during hydroxyurea therapy.
    Iyamu EW; Cecil R; Parkin L; Woods G; Ohene-Frempong K; Asakura T
    Br J Haematol; 2005 Nov; 131(3):389-94. PubMed ID: 16225659
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term hydroxyurea treatment in children with sickle cell disease: tolerance and clinical outcomes.
    de Montalembert M; Brousse V; Elie C; Bernaudin F; Shi J; Landais P;
    Haematologica; 2006 Jan; 91(1):125-8. PubMed ID: 16434381
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Ulcers on the legs and feet: a seldom recognised side effect of hydroxyurea].
    Janssen JJ; Ossenkoppele GJ
    Ned Tijdschr Geneeskd; 2003 Aug; 147(31):1517-20. PubMed ID: 12924084
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preliminary report of a toxicity study of hydroxyurea in sickle cell disease. French Study Group on Sickle Cell Disease.
    de Montalembert M; Bégué P; Bernaudin F; Thuret I; Bachir D; Micheau M
    Arch Dis Child; 1999 Nov; 81(5):437-9. PubMed ID: 10519721
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of hydroxyurea on sperm count, motility and morphology in adult men with sickle cell or myeloproliferative disease.
    Grigg A
    Intern Med J; 2007 Mar; 37(3):190-2. PubMed ID: 17316339
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hydroxyurea therapy contributes to infertility in adult men with sickle cell disease: a review.
    DeBaun MR
    Expert Rev Hematol; 2014 Dec; 7(6):767-73. PubMed ID: 25242414
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hydroxyurea therapy in adult Nigerian sickle cell disease: a monocentric survey on pattern of use, clinical effects and patient's compliance.
    Adewoyin AS; Oghuvwu OS; Awodu OA
    Afr Health Sci; 2017 Mar; 17(1):255-261. PubMed ID: 29026400
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characteristics and outcome of connective tissue diseases in patients with sickle-cell disease: report of 30 cases.
    Michel M; Habibi A; Godeau B; Bachir D; Lahary A; Galacteros F; Fifi-Mah A; Arfi S
    Semin Arthritis Rheum; 2008 Dec; 38(3):228-40. PubMed ID: 18177923
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of hydroxyurea on the membrane of erythrocytes and platelets in sickle cell anemia.
    Covas DT; de Lucena Angulo I; Vianna Bonini Palma P; Zago MA
    Haematologica; 2004 Mar; 89(3):273-80. PubMed ID: 15020264
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Evaluation of clinical response by hydroxyurea in 132 patients with major sickle cell anemia].
    Elira Dokekias A; Okandze Elenga JP; Ndinga J; Sanogo I; Sangare A
    Tunis Med; 2005 Jan; 83(1):32-7. PubMed ID: 15881719
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reversible leg ulcer due to hydroxyurea in a case of chronic myeloid leukemia.
    Tripathi AK; Ahmad R; Sawlani KK
    J Assoc Physicians India; 2003 Oct; 51():1014-5. PubMed ID: 14719596
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hydroxyurea treatment for sickle cell disease: impact on haematopoietic stem cell transplantation's outcome.
    Brachet C; Azzi N; Demulder A; Devalck C; Gourdin A; Gulbis B; Klein A; Le PQ; Loop M; Sariban E; Ferster A
    Bone Marrow Transplant; 2004 Apr; 33(8):799-803. PubMed ID: 14767501
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hydroxyurea therapy for sickle cell disease in community-based practices: a survey of Florida and North Carolina hematologists/oncologists.
    Zumberg MS; Reddy S; Boyette RL; Schwartz RJ; Konrad TR; Lottenberg R
    Am J Hematol; 2005 Jun; 79(2):107-13. PubMed ID: 15929107
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hydroxyurea and lower leg ulcers.
    Nguyen TV; Margolis DJ
    Cutis; 1993 Oct; 52(4):217-9. PubMed ID: 8261806
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hydroxyurea in Pediatric Patients With Sickle Cell Disease: What Nurses Need to Know.
    Rees AL
    J Pediatr Oncol Nurs; 2016 Sep; 33(5):339-44. PubMed ID: 26611755
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.